View Clinical Trial (Medical Research Study)
Chromium's Effect on Insulin Resistance in Obesity - NCT00997659-11794(Clinical Trial 369946)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Stony Brook |
|
State:
|
|
NY |
| Zip Code: |
|
11794 |
| Conditions: |
|
Insulin Resistance - Obesity |
| Purpose: |
|
This research is to investigate the nutritional supplement chromium picolinate. A large
number of people use chromium picolinate from health food stores to improve the function of
the hormone insulin. The investigators are testing how effective this supplement is and are
also monitoring its safety. In patients with diabetes, chromium has been shown to increase
sensitivity to the hormone insulin. Since obesity can cause insensitivity or resistance to
insulin, the investigators are studying obese individuals with documented insulin
resistance. The investigators would like to know if chromium is also effective in treating
the insulin resistance associated with obesity.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
1. age > 18 years;
2. a BMI greater or equal to 30; AND
3. an abnormal 2 hour postprandial glucose (greater than 140 mg/dl but less than 200
mg/dl) following 75 grams of a glucose load.
Exclusion Criteria:
1. positive pregnancy test (all women must have a negative pregnancy test before
beginning protocol);
2. diagnosis of cancer;
3. acute illness of any sort, however, patients may be enrolled once they are stable;
4. hemoglobin less than 11.0 g/dl or hemodynamically unstable;
5. creatinine greater than or equal to 1.5 mg/dl;
6. liver dysfunction as evidenced by elevations in transaminases 2-fold higher than
upper limit of normal;
7. use of certain medications within the past month (e.g., glucocorticoids).
8. untreated hypertension (systolic BP > 150 mmHG, diastolic BP>IOO mmHG);
9. patients with diabetes mellitus;
10. hypogonadism;
11. abnormal thyroid function (serum T4 < 4 or > 12; TSH < 0.35 or > 5.5) (12) any
chronic liver or kidney disease; OR
12. polycystic ovarian syndrome. |
|
|
|
| Study is available at: |
|
Stony Brook University GCRC
Stony Brook, NY 11794
United States
Primary Contact:
Dennis Mynarcik, PhD
Email: dmynarcik@notes.cc.sunysb.edu
Phone: 631-444-3430
Secondary Contact:
Dennis Mynarcik, PhD
Email: dmynarcik@notes.cc.sunysb.edu
Phone: (631) 444-3430 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 23, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|